LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Kodu・Aktsiate loetelu・uniQure NV

uniQure NV

Suletud

14.67 -6.08

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.55

Max

15.46

Põhinäitajad
By Trading Economics
Sissetulek	43M -37M
Müük	1.9M 5.6M
Kasumimarginaal	-666.056
Töötajad	221
EBITDA	2.4M -49M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+105.13% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	8. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-528M 995M
Eelmine avamishind	20.75
Eelmine sulgemishind	14.67

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

10.05 / 14.75 Toetus ja vastupanu

uniQure NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. märts 2026, 13:13 UTC

Suurimad hinnamuutused turgudel

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9. jaan 2026, 15:14 UTC

Suurimad hinnamuutused turgudel

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3. nov 2025, 13:34 UTC

Suurimad hinnamuutused turgudel

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24. sept 2025, 18:51 UTC

Tulu

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

uniQure NV Prognoos

Hinnasiht

By TipRanks

105.13% tõus

12 kuu keskmine prognoos

Keskmine 32 USD 105.13%

Kõrge 70 USD

Madal 9 USD

Põhineb 12 Wall Streeti analüütiku instrumendi uniQure NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi uniQure NV aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

10.05 / 14.75Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.